Back to search

Article

Repurposing Melatonin in dual-mode for Wilson disease therapy as a Copper Chelator and an antioxidant agent

2025-09-02

Abstract excerpt

Loss-of-function mutations in copper-ATPase ATP7B underlie Wilson disease (WD), a disorder characterized by hepatic copper accumulation and severe hepato-neuropathology. Existing chelation therapeutics remove excess copper but lack intrinsic antioxidant capacity and frequently cause systemic toxicity. Here we evaluate melatonin, an FDA-approved indoleamine with antioxidant and putative metal-chelating activity, as...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1d884697-5a9a-5d1b-bd61-d11aff86cc5f
DOI
10.1101/2025.08.30.673002
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Repurposing Melatonin in dual-mode for Wilson disease therapy as a Copper Chelator and an antioxidant agentDOI 10.1101/2025.08.30.673002
Select a neighboring publication to make it the new centre.